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ABSTRACT
Objective To evaluate serum potassium levels and 
rates of hypokalaemia in patients treated with liquorice-
containing Japanese traditional Kampo-medicines 
Yokukansan (YK) and Yokukansan-ka-chinpihange (YKCH).
Design Retrospective cohort study.
Setting Patients receiving YK preparations for dementia 
and other psychiatric disorders in the University of 
Tsukuba Hospital in Japan.
Participants 389 patients (male/female: 174/215, 
68.6±16.1 years) were treated with YK preparations for 
231 days (range 6–2788 days). Patients whose potassium 
levels were <3.6 mEq/L before administration of YK 
preparations, and drug non-compliant patients, were 
excluded.
Main outcome measure The occurrence rate of 
hypokalaemia and assessment of the risk factors for YK 
preparation-induced hypokalaemia.
Results Of the 389 patients treated with YK preparations, 
94 (24.2%) developed hypokalaemia (potassium 
levels <3.6 mEq/L) 34 days (range 1–1600 days) after 
administration of the preparations. 36 (38.3%) patients 
had co-administration with lower potassium-inducing 
drugs (LPIDs; diuretics, glucocorticoids, mineralocorticoids 
and glycyrrhizin), which was more frequent in the 
patients without hypokalaemia (17.3%) (p<0.05). A Cox 
proportional hazard model identified four risk factors for 
hypokalaemia: YK administration (not YKCH) (HR 3.093, 
95% CI 1.408 to 6.798), co-administration of LPIDs (HR 
2.743, 95% CI 1.754 to 4.289), hypoalbuminaemia at 
baseline (HR 2.145, 95% 1.360 to 3.384), and full dosage 
administration (7.5 g/day) (HR 1.600, 95% CI 1.005 to 
2.549).
Conclusions Serum potassium monitoring should be 
done at least monthly in patients with the following 
risk factors: LPID co-administration, YK administration, 
hypoalbuminaemia, and full dosage administration.
InTRODuCTIOn
Yokukansan (YK)  and Yokukansan-ka-chim-
pihange (YKCH) are Japanese kampo 
(traditional) medicines—consisting of seven 
and nine crude drug extracts, respectively 
(table 1)—for the treatment of restlessness 
and agitation in children.1 Current use of 
YK preparations focuses on the treatment 
of behavioural and psychological symptoms 
of dementia (BPSD) in patients with Alzhei-
mer’s disease and Lewy body dementia.1–10 
This trend has altered the YK target patient 
population from children to the elderly 
in just the past decade.11 An increase in 
adverse effects such as liver dysfunction, 
interstitial pneumonia, pseudoaldostero-
nism, and rhabdomyolysis have been found 
in dementia patients, leading to the revision 
of the YK preparation package insert.12 These 
adverse effects may be due to the change in 
target patient age (juvenile to elderly) and 
interactions with concomitant drugs being 
administered for the complications.11 13
Since both YK preparations contain 
liquorice as the crude drug glycyrrhiza, they 
have liquorice-induced pseudoaldostero-
nism characterised by hypertension and 
hypokalaemia as their essential adverse 
effect.14 This adverse effect has been ignored 
to date because the glycyrrhiza content of 
the preparation (1.5 g/day) is less than the 
2.5 g/day which is considered to increase 
the risk of liquorice-induced pseudoaldoste-
ronism among Kampo-medicines containing 
glycyrrhiza15 (table 2). However, several obser-
vations have revealed that the occurrence of 
Liquorice-induced hypokalaemia in 
patients treated with Yokukansan 
preparations: identification of the risk 
factors in a retrospective cohort study
Saori Shimada,1 Tetsuaki Arai,2 Akira Tamaoka,3 Masato Homma1
To cite: Shimada S, Arai T, 
Tamaoka A, et al.  Liquorice-
induced hypokalaemia 
in patients treated with 
Yokukansan preparations: 
identification of the risk 
factors in a retrospective 
cohort study. BMJ Open 
2017;7:e014218. doi:10.1136/
bmjopen-2016-014218
 ► Prepublication history for 
this paper is available online. 
To view these files please visit 
the journal online (http:// dx. doi. 
org/ 10. 1136/ bmjopen- 2016- 
014218).
Received 9 September 2016
Revised 27 March 2017
Accepted 8 May 2017
1Department of Pharmaceutical 
Sciences, Graduate School 
of Comprehensive Human 
Sciences, University of Tsukuba, 
Tsukuba, Japan
2Department of Psychiatry, 
Graduate School of 
Comprehensive Human 
Sciences, University of Tsukuba, 
Tsukuba, Japan
3Department of Neurology, 
Graduate School of 
Comprehensive Human 
Sciences, University of Tsukuba, 
Tsukuba, Japan
Correspondence to
Dr Masato Homma;  
 masatoh@ md. tsukuba. ac. jp
Research
Strengths and limitations of this study
 ► This is the first report to identify the risk factors 
for hypokalaemia as an initial symptom of 
pseudoaldosteronism in patients treated with 
YK preparations containing small amounts of 
glycyrrhiza (1.5 g/day).
 ► Patient data, including backgrounds and laboratory 
data, are under the sole stewardship of the University 
of Tsukuba Hospital.
 ► Since this is a retrospective cohort study, blood 
sampling intervals for assessing serum potassium 
and other laboratory data were not fixed.
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Table 1 Components of YK preparations
Constituent herbs
Weight (g/day)
YK* YKCH†
JP Atractylodes Lancea Rhizome 4.0 4.0
JP Poria Sclerotium 4.0 4.0
JP Cnidium Rhizome 3.0 3.0
JP Uncaria Hook 3.0 3.0
JP Japanese Angelica Root 3.0 3.0
JP Bupleurum Root 2.0 2.0
JP Glycyrrhiza 1.5 1.5
JP Pinellia Tuber – 5.0
JP Citrus Unshiu Peel – 3.0
*7.5g of Tsumura YK extract granules contains 3.25 g of a dried 
extract of the mixed crude drugs.
†7.5g of Tsumura YKCH extract granules contains 4.5 g of a dried 
extract of the mixed crude drugs.
JP, The Japanese Pharmacopoeia; YK, Yokukansan; YKCH, 
Yokukansan-ka-chimpihange.
Table 2 Commercially available Kampo-medicines 
containing glycyrrhiza
Glycyrrhiza 
contents
(g/day)
Number of
Kampo-
medicines Examples
6.0 1 Shakuyakukanzo-to
5.0 2 Kanbakutaiso-to, 
Shakuyakukanzo-bushi-to
3.0 11 Ninjin-to, Oren-to, Shoseiryu-to, 
etc
2.5 1 Hangeshashin-to
2.0 38 Kakkon-to, Shosaiko-to,
Tokishigyaku-ka-goshuyushokyo-
to, etc
1.5 24 Hochuekki-to, Yokukansan, 
Yokukansan-ka-chimpihange, etc
1.0 31 Chotosan, Ninjinyoei-to, 
Rikkunshi-to, etc
hypokalaemia caused by YK preparations is unexpectedly 
high and may develop into life-threatening events such 
as congestive heart failure and rhabdomyolysis, which 
requires cessation of drug administration.16–18
In the present study, we retrospectively investigated the 
change in serum potassium levels in patients treated with 
YK preparations to assess the risk factor for hypokalaemia 
as an initial symptom of pseudoaldosteronism.
MeThODS
YK preparations
YK preparations (YK and YKCH) were obtained in a 
commercially available granule form (Tsumura & Co, 
Tokyo, Japan), prepared from a mixture of seven and 
nine crude drug extracts, respectively (table 1). These 
traditional medicines are approved for medical use in 
Japan. The daily dose of both YK preparations is 7.5 g/
day as the granule, which contains a dried extract of 
the mixed crude drugs of YK (3.25 g) or YKCH (4.5 g) 
as shown in table 1. The glycyrrhiza content for both YK 
and YKCH was the same as the daily dose extracts (1.5 g) 
(tables 1 and 2).
Patients and study design
Three hundred and eighty-nine patients (174 males and 
215 females, mean±SD age 68.6±16.1 years) receiving 
YK preparations for BPSD or other psychiatric disorders 
were enrolled at the University of Tsukuba Hospital from 
March 2007 to January 2016 (table 3). One hundred and 
eighty-four patients were treated as outpatients and 205 
were admitted during the trial. Three hundred and twen-
ty-three patients were treated with YK and 66 with YKCH 
for 231 days (range 6–2788 days). YK preparations were 
given orally before or after meals at full dose strength 
(2.5 g three times a day; 7.5 g/day) or a reduced dose (2.5 
g once or twice a day; 2.5–5.0 g/day) based on patient 
symptoms; 229 patients (58.9%) received a full dose of 
YK preparation. Non-compliant patients as well as those 
whose pre-administration serum potassium level was <3.6 
mEq/L were excluded from the study. Changes in labora-
tory data, including serum potassium, sodium, chloride, 
aspartate aminotransferase, alanine aminotransferase, 
blood urea nitrogen, serum creatinine and albumin, 
and co-medication were retrospectively investigated via 
medical records before and after administration of YK 
preparations.
Statistical analyses
Statistical parameters were ascertained using SPSS soft-
ware (International Business Machines Corp, Armonk, 
New York, USA). Statistical analyses were performed by 
the Mann-Whitney test and χ2 test for comparing differ-
ences between hypokalaemic and non-hypokalaemic 
groups. The cut-off threshold for hypokalaemia was 
determined by a receiver operating characteristic (ROC) 
curve. Intergroup differences in patients treated with 
and without lower potassium-inducing drugs (LPIDs; 
diuretics, glucocorticoids, mineralocorticoids and glycyr-
rhizin preparations) were analysed by the Kaplan-Meier 
method. A Cox proportional hazard model was employed 
to identify risk factors for hypokalaemia. A value of p<0.05 
was considered to be statistically significant.
ReSulTS
Ninety-four patients (24.2%) developed hypokalaemia 
(potassium levels <3.6 mEq/L) during the study period 
(table 3). The median time to develop hypokalaemia 
was 34 days (range 1–1600 days) after administration of 
YK preparations (table 3) at which the cumulative rate 
of hypokalaemia was 12.7% by Kaplan-Meier analysis 
(figure 1).
Significant differences between hypokalaemic and 
non-hypokalaemic patients were observed and attributed 
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Table 3 Demographic data of the subjects
Hypokalaemic Non-hypokalaemic p Value
Number of patients (male/female) 94 (35/59) 295 (139/156) 0.093
Age (years) 69.5±16.7 68.2±15.9 0.334
Body weight (kg)† 51.2±12.8 54.6±14.5 0.182
Disease (dementia/other psychiatric disorder) 42/52 157/138 0.149
YK preparation treatment
  YK/YKCH 86/8* 237/58 0.012
  Full dose 66 (70.2%)* 163 (55.3%) 0.010
  Dosing periods (days) 169 (8 to 2280)* 266 (6 to 2788) 0.048
  Dosing period until hypokalaemia (days) 34 (1 to 1600) – –
Co-administration of LPIDs 36 (38.3%)* 51 (17.3%) <0.001
  Diuretics (loop/thiazide) 10/4 15/7 –
  Glucocorticoids/mineralocorticoid 18/0 23/2 –
  Glycyrrhizin preparation 7 18 –
Serum potassium (mEq/L)
  Baseline 4.0±0.3* 4.2±0.4 <0.001
  Minimum 3.2±0.3* 4.1±0.3 <0.001
  ∆ potassium −0.7 (−3.0 to −0.1)* −0.1 (−1.3 to 1.1) <0.001
Laboratory abnormality at baseline‡
  Aspartate aminotransferase (U/L) 11 (11.7%) 24 (8.1%) 0.293
  Alanine aminotransferase (U/L) 14 (14.9%)*  29 (9.8%) 0.009
  Albumin (g/dL) 47 (50.0%)* 86 (29.2%) <0.001
  Blood urea nitrogen (mg/dL) 37 (39.4%)* 78 (26.4%) 0.017
  Creatinine (mg/dL) 28 (29.8%) 107 (36.3%) 0.250
  Sodium (mEq/L) 7 (7.4%) 17 (5.8%) 0.555
  Chloride (mEq/L) 11 (11.7%) 39 (13.2%) 0.702
The data are presented as number of patients, mean±SD or median (range).
*p<0.05 versus non-hypokalaemia.
†The number of patients whose weight was recorded  was  85 with hypokalaemia and 224 with non-hypokalaemia.
‡The number of patients with abnormal laboratory data at baseline.
The normal ranges for laboratory data are: aspartate aminotransferase, 8.0–38.0 U/L; alanine aminotransferase, 4.0–44.0 U/L; albumin, 
3.8–5.3 g/dL; blood urea nitrogen, 8.0–20.0 mg/dL; creatinine, 0.61–1.04 mg/dL (male) and 0.47–0.79 mg/dL (female); sodium, 135.0–147.0 
mEq/L; chloride, 98.0–108.0 mEq/L.
LPIDs, lower potassium-inducing drugs; YK, Yokukansan; YKCH, Yokukansan-ka-chimpihange.
to the type of drug used (YK or YKCH), the dosed amount, 
and dosing period. Compared with the non-hypokalaemic 
group, the hypokalaemic group received YK more often 
than YKCH (91.5% vs 80.3%) as well as more full dosing 
amounts (70.2% vs 55.3%, p<0.05) (table 3). The dosing 
period in hypokalaemic cases was significantly shorter 
than in non-hypokalaemic cases (169 days, range 8–2280 
days vs 266 days, range 6–2788 days, p<0.05) (table 3).
Of the patients with hypokalaemia, 36 (38.3%) were 
receiving concomitant doses of LPIDs, which was more 
frequent in the patients without hypokalaemia (17.3%) 
(p<0.05) (table 3). Mean serum potassium at baseline in 
the hypokalaemic group was also lower than in the non-hy-
pokalaemic group (p<0.001), even though their values were 
within the normal range. The reduction for serum potas-
sium (∆ potassium) after administration of YK preparations 
was pronounced in the hypokalaemic group compared with 
the non-hypokalaemic group (−0.7, −3.0 to −0.1 mEq/L vs 
−0.1, −1.3 to 1.1 mEq/L, p<0.001) (table 3).
 Hypokalaemic patients more often displayed abnormal 
values of alanine aminotransferase, albumin and blood 
urea nitrogen at baseline than the non-hypokalaemic 
group (14.9% vs 9.8%, 50.0% vs 29.2% and 39.4% vs 
26.4%, respectively, p<0.05). A higher rate of hypoal-
buminaemia (albumin <3.8 g/L) was also observed in 
hypokalaemic patients (45.7% vs 28.8%, p<0.05), with 
concomitant minimum potassium levels during the 
administration of YK preparations (data not shown).
A Cox proportional hazard model based on univari-
able and multivariable analysis identified four risk factors 
for YK preparation-induced hypokalaemia: YK adminis-
tration (not YKCH) (HR 3.093, 95% CI 1.408 to 6.798), 
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Table 4 Hazard ratios for hypokalaemia in patients treated with YK preparations*
Risk factors
Univariable analysis Multivariable analysis
Hazard ratio (95% CI) p Value Hazard ratio (95% CI) p Value
YK administration (not YKCH) 2.84 (1.37 to 5.87) 0.005 3.09 (1.41 to 6.80) 0.005
LPIDs co-administration 2.88 (1.89 to 4.38) <0.001 2.74 (1.75 to 4.29) <0.001
Hypoalbuminaemia† 2.95 (1.94 to 4.49) <0.001 2.15 (1.36 to 3.38) 0.001
Fully-dosed amount 1.64 (1.05 to 2.55) 0.029 1.60 (1.01 to 2.55) 0.048
Female 1.36 (0.89 to 2.06) 0.153 1.32 (0.85 to 2.03) 0.215
Age 1.00 (0.99 to 1.02) 0.537 1.00 (0.99 to 1.02) 0.673
Serum potassium† (≥4.1 mEq/L) 0.36 (0.24 to 0.54) <0.001 0.45 (0.29 to 0.70) <0.001
*Cox proportional hazard model was used.
†Determined at baseline.
LPIDs, lower potassium-inducing drugs; YK, Yokukansan; YKCH, Yokukansan-ka-chimpihange.
co-administration of LPIDs (HR 2.743, 95% CI 1.754 to 
4.289), hypoalbuminaemia at baseline (HR 2.145, 95% CI 
1.360 to 3.384), and full-dose administration of YK prepa-
rations (7.5 g/day) (HR 1.600, 95% CI 1.005 to 2.549) 
(table 4). On the other hand, baseline potassium levels 
≥4.1 mEq/L, established as the optimal threshold to predict 
non-hypokalaemia, were a reverse risk factor for hypoka-
laemia (HR 0.450, 95% CI 0.288 to 0.702) (table 4).
To assess the effects of LPIDs co-administration on 
the occurrence of hypokalaemia, the time between 
administration of YK preparations and development 
of hypokalaemia was compared between groups with 
and without LPIDs (figure 2). Patients treated with 
concomitant LPIDs showed a shorter time-to-occur-
rence for hypokalaemia than those without concomitant 
LIPDs (p<0.001) (figure 2) .
Nine patients discontinued YK preparations due to 
hypokalaemia and each had the risk factors indicated 
in table 5. Seven patients (except for cases 4 and 7) had 
multiple risk factors. Cases 1 and 2 developed severe hypo-
kalaemia, with potassium levels <2.1 mEq/L, and were 
found to have been co-administered a thiazide diuretic 
or presented with rhabdomyolysis, respectively (table 5).
DISCuSSIOn
Occurrence rate of hypokalaemia when using YK 
preparations
Both YK preparations contain 1.5 g/day of glycyrrhiza 
(table 1), which is much less than the Shakuyakukanzo-to 
(6.0 g/day of glycyrrhiza) preparation that is thought to 
possess the highest risk for pseudoaldosteronism among 
the Kampo-medicines (table 2).19–21 However, the Japa-
nese Adverse Drug Event Report (JADER), a spontaneous 
adverse events reporting system, currently reports that 
YK-induced pseudoaldosteronism rates are comparable 
with those of Shakuyakukanzo-to, even though the possible 
risk should be low in terms of the glycyrrhiza content.19 20 
Present results seemed to confirm the JADER’s report; 
hypokalaemia was found in high frequency, with 24.2% 
of the patients having been treated by YK preparations. 
This rate is comparable with a previous investigation in 
elderly patients, where 17% of patients treated with YK 
developed hypokalaemia.22
On the other hand, an adverse drug reaction (ADR) 
frequency investigation on YK for ethical use reported 
that hypokalaemia occurred in 1.3% of patients treated 
with YK,13 which was considerably lower than our obser-
vation. Several factors may explain this difference in the 
occurrence rate of hypokalaemia. One possible reason is 
patient background in terms of disease severity, compli-
cations and concomitant drug administration. Eighty per 
cent of the subjects in the ADR investigation were outpa-
tients and 61.9% of the patients had no complications 
and no medication for dementia.13 On the other hand, 
this study enrolled patients who presented with compli-
cating psychiatric disorders (48.8%) and received various 
medications, including LPIDs such as diuretics, glucocor-
ticoids, mineralocorticoids and glycyrrhizin preparations. 
Another possible reason is the observation periods 
between the studies. The ADR frequency investigation 
did not track adverse events longer than 52 weeks after 
starting YK administration.13
Serum potassium monitoring to prevent YK preparation-
induced hypokalaemia
Liquorice-induced pseudoaldosteronism due to 
Kampo-medicines can escalate into a serious event that 
makes hospitalisation necessary. The mechanism seems 
to be clear.23–26 Glycyrrhetinic acid (GA), a metabolite of 
glycyrrhizin (GL) contained in liquorice, has been found 
to be the major substance responsible for pseudoaldoste-
ronism. GA inhibits 11β-hydroxysteroid dehydrogenase 
type 2 (11β-HSD 2), which catalyses the conversion of 
cortisol to cortisone and prevents the binding of cortisol 
to the mineralocorticoid receptor (MCR) in the mineralo-
corticoid target tissues. This inhibition leads to increased 
cortisol levels in the tissues and excess cortisol binding to 
the MCR with the same affinity as aldosterone.23 24 The 
MCR activation increases sodium reuptake and inhibits 
potassium reabsorption in the kidney, resulting in 
hypertension, metabolic alkalosis and hypokalaemia.25 
Monitoring of serum potassium levels, therefore, is useful 
for the early detection and assessment of the severity of 
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pseudoaldosteronism. Our present results suggest that 
serum potassium levels should be checked the first month 
after starting YK preparations, because the median time 
for hypokalaemia onset was 34 days after administra-
tion (table 3). Serum potassium monitoring should be 
continued during treatment, because late onset pseudo-
aldosteronism was found to occur up to 3 years after final 
administration of Kampo-medicines containing glycyr-
rhiza.27
Risk factors for YK preparation-induced hypokalaemia
We found four risk factors associated with hypokalaemia 
in patients with heterogeneous clinical backgrounds 
(table 4). The risk of hypokalaemia during YK treatment 
was 3.09 times higher than that of YKCH (table 4). One 
possible explanation of this finding may be due to the 
difference in GL content between YK and YKCH, even 
though the glycyrrhiza content is the same (1.5 g/day) 
as shown in table 1. Kampo-medicines, including YK 
preparations, are spray-dried herbal extracts (table 1). A 
mixture of seven or nine crude drugs are added to water 
and boiled, filtered, concentrated and then the resulting 
decoctions are further spray-dried to yield the extract for 
making YK preparations. In this manufacturing process, 
the wet extraction rate of GL may differ between YK and 
YKCH due to variations in the combination of crude drugs 
and the pH value of their decoctions.28 A resultant higher 
GL content for YK might therefore present a higher risk 
of hypokalaemia compared with YKCH.
Patients co-administered with LPIDs were 2.74 times 
more likely to develop hypokalaemia (table 4, figure 2) 
and experience a shorter time-to-onset compared with 
YK preparations alone (figure 2). Among the LPIDs, loop 
and thiazide diuretics attract special attention because 
they are frequently prescribed for dementia patients with 
hypertension (data not shown). Severe hypokalaemic 
cases with low potassium levels of 1.9 mEq/L had received 
thiazide diuretics concomitantly (table 5).
Patients with hypoalbuminaemia had a 2.15 times higher 
rate of hypokalaemia (table 4). Since 99.9% of circulating 
GA are bound to albumin,29 hypoalbuminaemia may 
increase the unbound fraction of GA through pharma-
cokinetic alteration, resulting in an enhancement of the 
pharmacological actions of GA. Yoshino and colleagues 
have suggested that hypoalbuminaemia was a risk factor for 
pseudoaldosteronism in three other Kampo-medicines.30 
The present results are the first to report that hypoalbu-
minaemia is a possible risk factor for liquorice-induced 
hypokalaemia due to YK preparations.
The occurrence of hypokalaemia might be dose depen-
dent in patients treated with YK preparations because 
full-dose YK preparations (7.5 g/day) increased the risk 
more than 1.60 times compared with a reduced dose 
(table 4). This observation is consistent with previous 
reports suggesting that liquorice-induced pseudoaldoste-
ronism was found in a dose-dependent manner.20 21 Since 
a majority of the dementia patients taking YK prepara-
tions were elderly, the reduced dose is recommended 
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for any patients with risk factors for pseudoaldostero-
nism. Although age was not identified as a risk factor for 
hypokalaemia in the present study, this might be due to a 
lack of comparison, as most of the patients investigated 
were elderly (mean age 68.6±16.1 years old). Initiation 
of full-dose YK preparations should therefore be avoided 
in elderly patients whose 11β-HSD activity might be low 
due to an age-dependent decline in kidney function.31 In 
fact, seven of nine patients who discontinued YK prepa-
rations due to hypokalaemia were over 70 years old and 
had multiple risk factors for hypokalaemia (table 5).
COnCluSIOn
Hypokalaemia was found at an unexpectedly high rate in 
patients receiving treatment with YK preparations, even 
though the liquorice content was relatively small. Four 
risk factors were found to be important in elderly patients 
receiving long-term treatment with YK preparations: YK 
versus YKCH administration, LPIDs co-administration, 
hypoalbuminaemia, and full dosage administration 
(7.5 g/day). It is recommended that serum potassium 
monitoring should be done at least monthly for the safe 
use of YK preparations in patients with multiple risk 
factors.
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